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USP’s  peptide  reference  standards  content  is typically  determined  using  an  HPLC  assay  against  an  external
standard  for  which  the  purity was determined  by a mass  balance  approach.  To explore  the  use of other
analytical  methods,  the  USP  Biologics  Department  conducted  a multi-laboratory  collaborative  study.  The
study  determined  the  inter-laboratory  variability  for peptide  quantitation  using  the  following  methods:
HPLC  assay,  quantitative  nuclear  magnetic  resonance  (qNMR)  spectroscopy,  or  amino  acid  analysis  (AAA).
The three  methods  were  compared  with  regard  to their  suitability  for quantitation  of the  nonapeptide
oxytocin.  In this  study,  the HPLC  assay  method  using  the same  peptide  bulk  material  as the standard
showed  the  lowest  inter-lab  variability.  The  coefﬁcient  of  variation  (%CV)  was  calculated  without  countinguantiﬁcation
PLC
MR
mino acid analysis (AAA)
the uncertainty  associated  with the  purity  assignment  of  the  standard  with  mass  balance.  The  proton
qNMR  method  is  a direct measurement  of  the  peptide  against  an  internal  standard,  which  is  not  difﬁcult
to  perform  under  common  laboratory  conditions.  Because  of the  simpler  operation  and shorter  analytical
time,  qNMR  as a primary  method  for peptide  reference  standard  value  assignment  deserves  further
exploration.
ublis© 2019  The  Authors.  P
. Introduction
Peptide therapeutics offer the beneﬁt of high selectivity of
iologics and often can be manufactured synthetically, and are con-
inuously gaining increased presence in the market [1]. To support
ccurate measurement of peptides in pharmaceutical development
nd quality control, peptide reference standards are required for
alibration in liquid chromatography, mass spectrometry or other
∗ Corresponding author.
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/).hed  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
assays [2]. Purity determination of peptide reference standards is
challenging and typically requires specialized methods.
The United States Pharmacopeia (USP) peptide reference stan-
dards (RS) have been typically packaged using bulk material. The
purity of the RS was  assigned by mass balance, which measures
all detectable impurities and subtracts these from 100%. Because
most peptides are very hygroscopic, such RS require users to weigh
out the RS in a controlled humidity environment, determine water
content at the time of use, and correct the water content in order
to calculate the standard solution concentration.
To improve the ease of use, packaging of peptide RS has shifted
to use lyophilization. This involves ﬁrst dissolving the peptide
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
Summary of Tests Performed by the Different Labs.
Lab No. qNMR AAA HPLC
1 x x
2  x x x
3  x x
4  x
5  x
6  x
7  x
8  x x
9  x
10  x
11  x
12  x
13  x06 C. Li et al. / Journal of Pharmaceutical a
ulk material in water with or without excipients, ﬁlling a pre-
etermined volume of the solution into ampoules or vials with high
recision (%CV of ﬁll weight is <0.50), the solvent is then removed
y sublimation via the process of lyophilization. The assigned value
f such prepared RS vial or ampoule is determined by assaying
gainst a well-characterized primary standard, which is usually the
ame peptide bulk material whose purity has been determined by
ass balance.
To improve the accuracy and precision of the assigned values of
eptide RS packaged by lyophilization, a collaborative study was
onducted. The study’s main objective was to evaluate and com-
are different analytical methods for the quantitation of peptide
aterials. By using the peptide RS candidates, the study focused
n comparing three analytical approaches, namely quantitative
uclear magnetic resonance (qNMR), amino acid analysis (AAA),
nd chromatographic (HPLC) mass balance assay. qNMR utilizes its
nique ability to achieve equal magnitude of response from mag-
etic nuclei, such as 1H, independent of chemical structure. AAA is
ased on quantifying stable amino acids following peptide hydrol-
sis. HPLC selectively quantiﬁes an analyte of interest against a
eference standard of the same analyte.
The collaborative study was conducted to address two goals:
To determine the inter-laboratory variability when measuring
peptides content using one of the following methods: HPLC assay,
qNMR, and AAA.
To compare the three methods above and determine which one
is the most suitable for the quantitation of peptide RS, ﬁlled and
lyophilized into ampoules or vials, that can be used by simply
reconstitution.
In addition to USP laboratories, 11 laboratories representing
ndustry, government, metrology, and standard-setting organiza-
ions participated in the study. Laboratory tests by all collaborators
ere performed between April and September 2016.
. Experimental Methods
.1. Materials and reagents
The materials and instruments used in this collaborative study
ncluded the following:
 USP Oxytocin Reference Standard candidate prepared by
lyophilization with high-precision ﬁll controlled by in-process
weight check to assess the vial-to-vial variability. The RS can-
didate was shipped to all collaborators from the USP, Rockville,
MD,  US.
 USP Oxytocin bulk material (lot B150122) was used as a standard
for HPLC quantiﬁcation.
 Deuterium oxide (D2O, Sigma, >99.9% D) was used as an NMR
solvent by all labs.
 USP Caffeine RS Lot K0K210 (0.998 mg/mg) was used as internal
standard for qNMR.
 Maleic acid (Sigma) (99.89%, certiﬁed against NIST SRM 350b ben-
zoic acid) was used as an alternative internal standard by one
lab.
 Deuterated 2,2,3,3-d Sodium 3-trimethylsilylpropionate (TSP-d4)
(Sigma, >99.9%) was used as an alternative internal standard by
one lab.
 In-house proline, leucine, and isoleucine candidate certiﬁed ref-
erence materials with purity assigned by qNMR were used as
primary calibrants and isotope labeled amino acids (Proline-
13C5: CIL, Lot # PR-18738, Cat # CLM-2260-H-0.1; Leucine-13C6:
CIL, Lot # PR-22233A, Cat # CLM-2262-H-0.1; and Isoleucine-14  x
Note: x represents lab participation.
13C6: CIL, Lot # PR-21540, Cat # CLM-2248-H-0.1) were used as
internal standards by Lab 3.
- l-(+)-Isoleucine, l-(+)-Leucine, l-(+)-Proline (Sigma, product #:
58879, 61819, 81709) were used as primary calibrants and iso-
tope labeled amino acids: Isoleucine (U-13C6), Leucine (U-13C6),
Proline (U-13C5, 15N) (Cambridge Isotope Laboratory, Product #:
CLM-2248, CLM-2262, CNLM-436) were used as internal standard
by Lab 7.
- Amino acid standard –H (Thermoscientiﬁc, Product #:catlog:
20088) was  used by Labs 2 and 9.).
In this study, the oxytocin samples were stored at −20 ◦C,
shipped on dry-ice, and the sample temperature was monitored
through international cold chain shipment. Lab 1 using the HPLC
method as described in Sections 2.8 and 2.9 checked the purity of
oxytocin after lyophilization. Total impurities after lyophilization
was 1.02% vs. 1.08% for the bulk material before lyophilization. The
observed difference is within experimental limit. An accelerated
stability study was conducted for the lyophilized oxytocin sample
stored at −20◦, 20◦, 37◦, and 45 ◦C. The total impurities (%) increase
rate vs.  the reciprocal of temperature in Kelvin was calculated using
Arrhenius equation. The correlation coefﬁcient (r2) is 0.9933. The
projected degradation rate at −20 ◦C is 0.014%/year by Arrhenius
equation. The major degradants observed are: carbimido oxytocin,
acetyloxytocin, -oxytocin dimer, and -oxytocin dimer.
2.1.1. Participating labs and study design
A total of 14 labs in 10 countries took part in the study. Each lab
is referred to by a code number, and Table 1 summarizes the tests
done by each lab. The names of the labs are listed below alphabet-
ically; note that there is no correlation to the order in Table 1.
Aspen Oss BV, Correllistraat 10, 5344 A G Oss, Netherlands
Australian Therapeutic Goods Administration (TGA), Symonston
ACT 2609, Australia
BCN Peptides S.A, Catalonia, Spain
Health Canada, Centre for Vaccine Evaluation, Ottawa ON,
Canada
Ipsen Manufacturing Ireland Ltd, Dublin, Ireland
Pharmaceutical and Medical Device Regulatory Science Soci-
ety of Japan (PMRJ), Japanese Pharmacopoeia Reference Standards
Laboratory (JPRS Lab), Osaka, Japan
Swedish Medical Products Agency (Läkemedelsverket), Uppsala,
Sweden
National Institute for Biological Standards and Control (NIBSC),
Potters Bar, United Kingdom
National Institute of Standards and Technology (NIST), Gaithers-
burg, MD,  United States
National Research Council of Canada (NRC), Ottawa ON, Canada
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0.1 mol/L sodium dihydrogen phosphate in water and (B) a mix-
ture of water and acetonitrile (50:50, v/v). The gradient program is
shown in Table 2.
Table 2
Gradient Program for HPLC Analysis.
Time(min) Mobile phase A (%) Mobile phase B (%)C. Li et al. / Journal of Pharmaceutical a
University of Nebraska, Omaha, NE, United States
US Pharmacopeial Convention (USP), Reference Standard Labo-
atory, Rockville, MD,  United States
US Pharmacopeial Convention (USP), Reference Standard Labo-
atory, Hyderabad, India
US Pharmacopeial Convention (USP), Global Biologics Labora-
ory, Rockville, MD,  United States
The procedures described in Sections 2.2 through 2.9 were fol-
owed by all participants’ laboratories.
.2. NMR  sample preparation
Three caffeine internal standard solutions were prepared gravi-
etrically at (2, 3, and 4) mmol/L, respectively, in D2O. Typical
affeine internal standards were prepared by transferring 0.8 mg,
.2 mg,  or 1.5 mg  of USP Caffeine RS to a 2 mL volumetric ﬂask,
issolved and diluted to volume with D2O (0.05 wt  % TSP-d4 for
hemical shift referencing). Alternatively, when using maleic acid
s internal standard, the solution was prepared gravimetrically at
 mmol/L in D2O. The NMR  sample solution was prepared by adding
.5 mL  of the respective internal standard solution into each vial
f lyophilized oxytocin and mixing. Two vials were used at each
evel of internal standard solution. The oxytocin concentration was
pproximately 3.6 mmol/L.
.3. NMR  instrumentation
The NMR  measurement was performed by transferring an
liquot (e.g., 300 L) from each of the two vials into a suitable NMR
ube (e.g. 5-mm)  to combine them. The typical NMR  acquisition
arameters include using a 30◦ pulse, with a 30-second relax-
tion delay to ensure complete spin relaxation, and typically 64
cans. After data acquisition, Fourier transform, phasing, baseline
orrection, and signal integration was performed for the selected
eaks of oxytocin and for the internal standard (caffeine, maleic
cid, or TSP-d4). Alternatively, one lab (lab 3) measured the 1H
pin-lattice relaxation time (T1) for a sample containing oxytocin
nd internal standard in D2O prior to qNMR analysis, using the
cquisition parameters: 90◦ pulse with a relaxation delay of 50 s
approximately 7x the longest relevant T1) and 32 scans. NMR  spec-
rometers with magnetic ﬁeld strengths ranging from 300 MHz  to
00 MHz  were used by the collaborators.
.4. Quantiﬁcation by NMR
The determinations in this study were performed on 1D 1H NMR
pectra through the proportional comparison of the peak areas inte-
rated for both the selected signal from the internal standard and
rom the Oxytocin.
esult = (Ru/Rs)×(ns/4)×Cs×(1007.2/MWs)×V
here Ru is the sum of the peak areas of the signals corresponding
o 4 H of tyrosine, Rs is the peak area of internal standard, ns is the
umber of hydrogens generating the selected signals for integra-
ion, 4 is the four hydrogens from tyrosine of oxytocin, Cs is the
oncentration of the internal standard solution in mg/mL, 1007.2
s the molecular weight of oxytocin in g/mol, MWs is the molec-
lar weight of the internal standard in g/mol, V is the volume of
nternals standard solution pipetted into each vial (0.5 mL).
.5. AAA sample preparationThe sample solution was prepared by adding a known amount
f hydrolysis solution (6–12) mol/L HCl containing a preserva-
ive such as phenol or sodium sulﬁte) and an internal standardmedical Analysis 166 (2019) 105–112 107
such as norleucine or deuterated amino acids to each lyophilized
oxytocin sample vial. An aliquot of this solution was  transferred
into a hydrolysis vessel. The vessel was  evacuated and sealed by
melting and then heated at 110 ◦C–115 ◦C for 12 h to 24 h. The con-
tents of the hydrolysis vessel were cooled and dried in a vacuum.
The residue was  quantitatively dissolved in diluted HCl (typically
0.02 mol/L HCl). The amount of oxytocin was analyzed using a suit-
able amino acid analysis condition (derivatized or un-derivatized)
to determine the concentrations (in nmol/mL) of the stable amino
acids such as Asp, Glu, Gly, Ile, Leu, Phe, and Pro. The amount of
oxytocin was  calculated using the average number of nmol/mL of
the amino acids found to be stable.
2.6. Quantiﬁcation by AAA
For the amino acid quantitation, Lab 8 used post-column nin-
hydrin derivatization and Lab 9 used the pre-column OPA (ortho
phthalaldehyde)/FMOC (ﬂuorenylmethoxy chloroformate) amino
acid method. Labs 3 and 7 used isotope (13C)-labeled amino acid
as an internal standard to spike the sample and standard prior to
hydrolysis, and the amino acids were quantiﬁed by LC–MS/MS. The
peak responses selected from the stable amino acids (Asp, Glu, Gly,
Ile, Leu, Phe, and Pro) are used for quantiﬁcation.
Result = (Ru/Rs))×Cs×(1007.2)×V
Where Ru is the of the peak areas of the signals corresponding to
sample, Rs is the peak area of standard, Cs is the molar concentration
of the standard solution in mol/L, 1007.2 is the molecular weight
of oxytocin in g/mol, V is the cumulative sample solution volume
in mL.
2.7. HPLC sample preparation
The standard solutions were prepared in triplicate. The sample
solutions were prepared by reconstitution. Typical sample prepa-
ration was  done by pipetting 4.0 mL  of water into each vial, and
then mixing well by invertion. A 1:25 dilution was  then made with
mobile phase A (e.g.: 2.0 mL  of the solution was transferred into a
50 mL  vol ﬂask, and dilute to vol with mobile phase A). Each solu-
tion was  injected in duplicate. The concentrations of standard and
sample solutions were 0.02 mg/mL  in mobile phase A. The purity
of the oxytocin standard was  taken into account when generat-
ing the standard solution, the ﬁnal concentration of oxytocin is
0.02 mg/mL.
2.8. HPLC instrumentation
A C18 column (250 mm × 4.6 mm,  5 m,  e.g., Waters Symmetry)
was used for the gradient elution. The ﬂow rate was 1.5 mL/min.
Oxytocin was detected at 220 nm (UV), the column temperature
was set to either 25 ◦C or 40 ◦C. The standard and sample injection
volumes were set at 100 L. The mobile phases consisted of (A)0 70 30
20  50 50
23  70 30
30  70 30
108 C. Li et al. / Journal of Pharmaceutical and Biomedical Analysis 166 (2019) 105–112
Table 3
Results of qNMR Tests (mg  of oxytocin per vial).
qNMR Sample No. Lab 1 Lab 2 Lab 3 Lab 4 Lab 5 Lab 6
Day 1
1 1.955 1.813 1.863 1.747 1.631 1.931
2  1.852 1.851 1.802 1.754 1.656 1.882
3  1.800 1.788 1.793 1.766 1.632 1.865
4 1.876 1.732 1.806 1.747 1.661
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Table 4
qNMR Statistical Analysisa (mg of oxytocin per vial).
Source Variance Standard deviation
(SD)
Relative standard
deviation (%RSD)
Reproducibility
(lab to lab)
0.0072 0.0851 4.73%
Repeatability
(sample to sample)
0.0011 0.0332 1.85%
Day  2 5  1.865 1.823 1.818 1.755 1.65
6  1.834 1.803 1.831 1.798 1.664
.9. Quantiﬁcation by HPLC
The oxytocin peak responses of the injections of sample and
tandard measured by HPLC are used for quantiﬁcation.
esult = (rU/rT)×Cs × V
here rU is the peak response from sample solution, rT is the peak
esponses from standard solution, Cs is the concentration of the
tandard solution in mg/mL, V is the cumulative sample solution
olume in mL.
. Results and discussion
According to ICH Q2 [3], precision may  be considered at three
evels: repeatability, intermediate precision, and reproducibility.
epeatability is assessed by performing multiple determinations
f the same sample on the same day(s) by the same analyst and
nstrument in the same lab. Intermediate precision involves assess-
ng typical variations in factors such as day, analyst, and equipment
ithin the same lab. Reproducibility is assessed by means of an
nter-laboratory trial. Reproducibility should be considered with
egard to standardization of an analytical procedure. There were
any published results that have evaluated the repeatability and
ntermediate precision of an HPLC assay, qNMR, and AAA within a
ingle lab. In this study, the reproducibility or inter-lab precision
variability) is the key focus. The data were analyzed using SAS Proc
ixed (Windows version 9.4). Laboratory is an assumed random
ffect to allow for correlation of results within laboratory.
The HPLC method was an established USP compendial method.
PLC methods in the USP monographs are commonly validated fol-
owing well recognized ICH guidelines. The qNMR and AAA used
n this study are neither compendial nor validated. Currently, the
alidation of qNMR on a speciﬁc analyte such as oxytocin is not
eported in the literature.
.1. Comparison of method precision
.1.1. qNMR results
Six participating labs performed a qNMR analysis, and each
ested a total of six samples. Sample numbers 1–3 were prepared
nd tested on the same day and samples 4–6 were prepared and
ested on a different day. Samples 1 and 4 were tested using an
nternal standard (caffeine) with a concentration of 2 mmol/L, sam-
les 2 and 5 were tested using an internal standard (caffeine) at
 mmol/L, and samples 3 and 6 were tested using an internal stan-
ard (caffeine) at 4 mmol/L except for Lab 6. Lab 3 tested using
affeine [(2, 3, and 4) mmol/L] as an internal standard for Day 1
nd maleic acid (2 mol/L) as an internal standard for Day 2. Lab 6
sed deuterated trimethylsilylpropionic acid (TSP-d4) as the inter-
al standard instead of caffeine or maleic acid, and Lab 6 only tested
ne sample at each concentration. The results (mg  of oxytocin per
ial) appear in Table 3.
Lab 1 used a 600 MHz  NMR  spectrometer with caffeine
s the internal standard. The signals of four aromatic hydro-
ens at 6.8 ppm–7.2 ppm of oxytocin (averaged) and the singleta The mean for all six labs was 1.798 mg with 95% conﬁdence interval:
1.707 mg–1.888 mg.  None of the labs’ results were excluded.
corresponding to the aromatic hydrogen (1H) of caffeine at approx-
imately 7.9 ppm were used for quantitation.
Lab 2 used a 500 MHz  NMR  spectrometer and caffeine as the
internal standard. Prior to qNMR analysis, the 1H spin-lattice relax-
ation time (T1) was  measured for a sample containing oxytocin
and internal standard in D2O. The signals of four hydrogens at
6.8 ppm–7.2 ppm of oxytocin (averaged) and the singlet corre-
sponding to the aromatic (1H) of caffeine at approximately 7.9 ppm
were used for quantitation.
Lab 3 used a 600 MHz  NMR  spectrometer and both caffeine
and maleic acid as internal standards. The signals of four aromatic
hydrogens at 6.8 ppm–7.2 ppm of oxytocin (separately or aver-
aged gave comparable results) and the singlet corresponding to the
methyl (3H) of caffeine at 3.4 ppm–3.5 ppm were used for quantita-
tion for samples 1–3. With the alternative internal standard, maleic
acid, the singlet signal at 6.22 ppm gave comparable results with
better repeatability for samples 4–6.
Lab 4 used 300 MHz  and 600 MHz  NMR  and caffeine as the inter-
nal standard. The signals of four hydrogens at 6.8 ppm–7.2 ppm of
oxytocin and the singlet at approximately 7.9 ppm corresponding
to the aromatic (1H) of caffeine were used for quantitation. This lab
reported that using either of the two  aromatic signals’ responses
(2H) or the sum of the two  aromatic signals (4H) gave comparable
assay results. Lab 4 also found that the 300 MHz  (equipped with
a broad band probe) and 600 MHz  (equipped with a cryo probe)
yielded comparable results, although there was larger measure-
ment uncertainty at 300 MHz  due to the limited resolution and
sensitivity.
Lab 5 used a 500 MHz  NMR  spectrometer and caffeine
as the internal standard. The signals of four hydrogens at
6.8 ppm–7.2 ppm of oxytocin (averaged) and the singlet corre-
sponding to the aromatic (1H) of caffeine at 7.9 ppm were used
for quantitation.
Lab 6 used a 700 MHz  NMR  spectrometer and TSP-d4 as the
internal standard. The signals of 11 hydrogens at 6.8 ppm–7.2 ppm
(4H), 2.8 ppm–2.9 ppm (4H), and 2.1 ppm–2.3 ppm (3H) of oxy-
tocin (averaged) and the singlet at 0.0 ppm corresponding to three
methyl groups (9H) of TSP-d4 were used for quantitation.
Statistical analysis indicated that the sample mean is 1.798 mg
without excluding any lab, but if Lab 6 is excluded, because of
the lack of Day 2 results, it is 1.779 mg.  The lab-to-lab variance
(reproducibility) and the sample-to-sample variance within each
lab (repeatability) are summarized in Table 4.
3.1.2. AAA results
Five participating labs performed the AAA test, each lab tested
two samples per day over 2 days, for four samples per lab. The
results from one lab (Lab 8) was  invalidated due to inconsistent
responses of the amino acid standard solution. The results, mg  of
oxytocin per vial, from the four remaining labs are presented in
Table 5.Lab 2 used the hydrolysis condition as described in Section
2.3. The amino acids were quantiﬁed using pre-column OPA/FMOC
derivatization followed by HPLC analysis [4] against an amino acid
standard containing 17 amino acids derivatized concomitantly. The
C. Li et al. / Journal of Pharmaceutical and Biomedical Analysis 166 (2019) 105–112 109
Table  5
Results of AAA Test (mg  of oxytocin per vial).
Sample No Lab 2 Lab 3 Lab 7 Lab 9
1 1.775 1.807 1.740 1.620
2  1.735 1.833 1.713 1.644
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Table 6
AAA Statistical Analysisa (mg  of oxytocin per vial).
Source Variance SD RSD
Reproducibility (lab to lab) 0.0089 0.0942 5.44%
Repeatability(sample to sample) 0.0009 0.0308 1.78%
a The mean value for the four labs was 1.73 mg733 with 95% conﬁdence inter-
val:  1.580 mg–1.884 mg.  Five labs performed AAA testing but one lab’s results were
excluded due to the amino acids standard solution preparation error.
Table 7
Results of HPLC Assays (mg  of oxytocin per vial).
Sample No Lab 1 Lab 2 Lab 8 Lab 11 Lab 12 Lab 13 Lab 14
1 1.829 1.851 1.777 1.801 1.825 1.720 1.822
2  1.808 1.861 1.785 1.822 1.816 1.740 1.830
3  1.819 1.852 1.777 1.815 1.815 1.706 1.806
4  1.818 1.910 1.793 1.798 1.815 1.734 1.829
5  1.827 1.861 1.781 1.819 1.845 1.726 1.827
6  1.830 1.857 1.786 1.823 1.823 1.737 1.820
7  1.816 1.843 1.787 1.819 1.818 1.721 1.820
8  1.810 1.859 1.785 1.822 1.794 1.747 1.822
Table 8
HPLC Statistical Analysisa (mg of oxytocin per vial).
Source Variance SD RSD
Reproducibility (lab to lab) 0.00168 0.0410 2.3%
Repeatability (sample to sample) 0.00015 0.0123 0.7%
manufacturing process used for generating the oxytocin standard3  1.807 1.804 1.718 1.555
4  1.840 1.808 1.726 1.603
xytocin content was calculated using the average content of Gly,
le, Leu, and Pro.
Lab 3 analyzed samples as is without derivatization with LC–MS.
 6 mol/L HCl solution was used as the hydrolysis solution. The solu-
ion was heated at 110 ◦C for 48 h with constant stirring. There was
o sample preparation or clean-up after the hydrolysis to avoid
otential biases, only a 25-fold dilution was performed and used
 divert valve was to minimize contamination of the mass spec-
rometer by chloride ion. In-house standards for Leu, Ile, and Pro
ere used as primary standards. 13C-derivatives of all amino acids
ere spiked as internal standard for samples and standards prior to
ydrolysis. The analysis was carried onto a zwitterion hydrophilic
nteraction liquid chromatography (HILIC) column (ZIC®-HILIC,
00 mm × 2.1 mm,  3.5 m,  100 Å) purchased from Merck SeQuant.
he ﬂow rate was 0.1 mL/min at 25 ◦C with an injection volume of
 L. Mobile phases: (A) 10 mol/L ammonium acetate adjusted to
H 3.5 in H2O and (B) Acetonitrile (ACN). Mobile phases were pre-
ared from a 200 mmol/L solution of ammonium acetate adjusted
o pH 3.5 with glacial acetic acid, which was diluted 1:20 (v/v) with
ater and ACN, respectively. An isocratic elution was  performed
ith 80% B during 10 min. For MS  detection, a ThermoFisher TSQ
uantiva Triple Quad featuring an ESI interface was used. Source
arameters in positive ionization mode were set as follows: ESI
oltage of 4400 V, ion transfer tube temperature of 325 ◦C, vapor-
zer temperature of 280 ◦C, and collision gas pressure of 2.0 bar.
ompound-speciﬁc MS  parameters, i.e., collision energy (CE) and
onitoring ions (Q3), were optimized for every analyte individually
y infusing a standard solution of the target compounds. Dynamic
ultiple reaction monitoring (MRM)  was performed, setting the
etention times of the analytes, with a time window of 2 min  and a
well time of 100 ms.
Lab 7 analyzed samples via vapor phase hydrolysis with moni-
oring of Leu, Ile, and Pro. Samples were prepared by placing them
nto separate glass autosampler vial inserts along with isotopi-
ally labeled amino acids used as internal standards. The samples
ere vacuum centrifuged to dryness. Hydrolysis was performed
or 48 h at 118 ◦C in a sealed Teﬂon vessel (40 mL)  containing 2 mL
f 6 mol/L HCl. Each vessel also contained standards prepared for
xternal calibration with a ﬁve-point standard curve. The quan-
itation method was isotope-dilution mass spectrometry coupled
ith HPLC. Separation was achieved by using a SIELC Primesep
00 mixed-mode (ion-exclusion and reverse phase) analytical col-
mn  (2.1 mm x 250 mm,  5 m particles, 100 Å pore size at a ﬂow
ate of 200 L/min). An Agilent Inﬁnity 1290 UPLC system was
oupled in-line with an Agilent 6460 triple quadrupole mass spec-
rometer with a Jet Stream-equipped standard micro-ﬂow source.
 linear decreasing pH gradient [increasing TFA concentration from
.05% (v/v) to 0.45% (v/v)] in a 20% (v/v) organic/aqueous solvent
ACN/H2O) was used to chromatographically resolve amino acids.
olumn temperature was maintained at 15 ◦C. Mobile phases A and
 consisted of 0.5 mL/L and 4.5 mL/L TFA, respectively, in 200 mL/L
CN (aqueous). Tandem mass spectrometry was performed in pos-
tive polarity mode using unit resolution for multiple reaction
onitoring (MRM)  of the [M+H]+ of the precursor ions. One tran-ition was monitored for each amino acid and its isotopic internal
tandard. Four MRM  time segments were used for MS  data acqui-
ition. The ﬁrst 5 min  of the chromatography gradient were sent toa The mean value for the six labs was 1.807 mg with 95% conﬁdence inter-
val:1.769 mg–1.845 mg.
waste. Proline transitions were monitored from 5 min  to 13 min,
leucine/isoleucine from 13 min  to 16.5 min. External calibration
was performed via linear regression using the response and mass
ratios of the standards applied to the samples.
Lab 9 used the hydrolysis condition as described in Section 2.3
with 6N HCl at 110◦ for 21 h. The amino acids were quantiﬁed using
post-column ninhydrin derivatization with the EZChrom software
provided on the Hitachi L8800 to integrate chromatograms and
perform regression analysis using peak heights.
Statistical analysis indicated that the sample mean is 1.733 mg.
The lab-to-lab variance (reproducibility) and the sample-to-sample
variance within each lab (repeatability) are summarized in Table 6.
3.1.3. HPLC assay results
Eight participating labs performed the HPLC assay test. The
design of HPLC test is a one day test by each lab, eight samples
per lab. The results from one lab (Lab 10) was not included because
Lab 10 was unable to obtain stable water content by Karl-Fisher,
which implies insufﬁcient humidity control during the assay stan-
dard preparation. The results in mg  of oxytocin per vial from the
seven remaining labs appear in Table 7.
Statistical analysis indicated that the result of 1.910 mg by Lab
2 was an outlier. With this exclusion, the sample mean was 1.806.
The lab-to-lab variance (reproducibility) and the sample-to-sample
variance within each lab (repeatability) are summarized in Table 8.
All Labs used the same HPLC condition, as described in Sections
2.7–2.9. All collaborators also used the same USP oxytocin stan-
dard material as the HPLC assay test. The purity of the standard
on an anhydrous basis was calculated by mass balance (100 – total
HPLC impurities) × (100 — acetic acid – residual solvents – inor-
ganic residue)/(100 × 100), in which the total HPLC impurities and
acetic acid are calculated using the average of six labs’ results. Thematerial ensures that residual solvents and inorganic residue con-
tents were close to zero; this was tested and conﬁrmed by the USP
Reference Standard Lab. The water content of the standard material
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Table 9
HPLC Impurities and Acetic Acid Content (w/w%).
Lab 1 Lab 2 Lab 8 Lab 11 Lab 12 Lab 13
Total HPLC impurities detected in the standard 1.08 1.14 
Acetic acid content of the standard 7.81 7.83 
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sFig. 1. Plot of individual data for the peptide reference materials.
as measured with Karl-Fisher (KF) titration by each lab at the time
f use, and the KF results were used to correct the overall purity of
he standard used by each individual lab. The variability of the mass
alance result could be attributed to the differences between labs
n measured HPLC impurities and acetic acid content (Table 9).
.2. Results comparison
The three quantiﬁcation methods yielded comparable means:
.807 mg  by HPLC assay, 1.798 mg  by qNMR, and 1.73 mg  by AAA. In
his study, the HPLC assay yielded the least intra- and inter-lab vari-
bility. AAA appeared to have much higher intra-lab and inter-lab
ariability, compared with qNMR and HPLC. This higher variability
s further discussed in Section 3.2.2. The individual data of the three
ethods are illustrated in Fig. 1.
The seven labs that performed the HPLC assay used the same
PLC method, and all seven labs are highly proﬁcient in HPLC anal-
sis. Six labs performed the qNMR test, and ﬁve of them used a
imilar condition with the same internal standard—caffeine. Ini-
Fig. 2. A 600 MHz  NMR  spectrum of Oxytocin with interna0.93 0.97 0.80 0.60
7.81 7.52 7.97 7.90
tially, we  had anticipated better accuracy and precision for qNMR
analysis because the method uses a highly pure, simple compound
as the internal standard. We  provided a highly characterized USP
Caffeine RS to all six labs. Five of them reported results using
caffeine as the internal standard and one lab reported results
using in-house TSP-d4 as their internal standard. Labs 3 and 4
performed additional studies using alternative internal standards.
These results are discussed in Section 3.2.1.
3.2.1. Selection of internal standard for qNMR
In this study, ﬁve labs used caffeine as the internal standard for
quantiﬁcation; the typical 1H NMR  spectrum of oxytocin with caf-
feine is shown in Fig. 2. The chemical shift () of signal at 7.90 ppm
from caffeine and the two  signals from four hydrogen associated
with tyrosine of oxytocin can be measured easily for quantiﬁcation.
Caffeine was used as the internal standard by ﬁve laboratories.
The signals associated with caffeine at approximately 7.90 ppm
did not interfere with analyte oxytocin signals at 6.9 ppm to
7.2 ppm (see Fig. 2). Reproducible NMR  results thus were obtained
in replicate determinations and are consistent with the assay val-
ues determined by other analytical methods. The inter-laboratory
tests also conﬁrm the suitability of this internal standard as well as
the quantitation attempts, however most peptides have crowded
overlapping signals in the region of 2 ppm–4 ppm. It was  reported
that caffeine’s purine ring hydrogen (chemical shift 7.90 ppm) is
likely to be solvent- and/or concentration-dependent due to the
possibility of exchange, and may  not be optimal for quantiﬁcation.
However, the results obtained in the present work indicate that caf-
feine is a useful internal standard for quantiﬁcation of oxytocin in
D2O solution. Fig. 3 contains the 1H NMR  spectra of some typically
used NMR  internal standards for water-soluble compounds.
Maleic acid is readily available in pure form and has a simple
1H NMR  spectrum; the singlet proton signal is unlikely to overlap
with peptide signals, and may  be a more suitable qNMR inter-
nal standard, for quantiﬁcation of peptides, than caffeine. Another
alternative would be 3-sulfolene, that shows two signals at ca.
6.2 ppm and 4.0 ppm (Ref. [6]). Lab 3 compared the use of maleic
l standards caffeine (marked *) and TSP (marked †).
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Fig. 3. Comparison of 300 MHz 1H NMR  Spectra of internal standards and
Table 10
Oxytocin Content by qNMR.
Replicates Oxytocin content by qNMR
using caffeine as the
internal standard (mg/vial)
Oxytocin content by qNMR
using maleic acid as the
internal standard (mg/vial)
1 1.863 1.806
2 1.802 1.818
3 1.793 1.831
Average 1.819 1.818
%RSD 2.1% 0.7%
Note that selection of an appropriate internal standard is crucial for the result. Some
desired characteristics of the standard are: 1) ability to provide unique and stable
signals (chemical shifts), 2) high purity material is available, 3) soluble in different
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1MR  solvents, 4) easy handling for tasks such as weighing and transfer, 5) non-
olatile, 6) non-reactive, and 7) stable in the long term [5].
cid versus caffeine as an internal standard and the results are
hown in Table 10. A similar amount of oxytocin was  obtained with
oth standards, but the use of maleic acid provided better within-
ab precision (repeatability). Maleic acid displays one well resolved
inglet peak in the spectrum, in an often signal free part of the
pectrum.
.2.2. Observation of amino acid analysis
AAA, has been one of the earliest adopted technique for Peptide
uantiﬁcation measurement of the amino acids often proceeded
y liquid chromatography or liquid chromatography - tandem
ass spectrometry (LC–MS/MS), using carbon-13 labelled amino
cids as internal standards in most cases [6–9]. This approach
s well-established and has been validated through interna-
ional comparison exercises [10]. Peptide reference standard value
ssignment has typically been performed by amino acid analysis
ollowing peptide hydrolysis [JM3-6]. Several amino acids such as
eucine, proline, valine, and phenylalanine are stable under the
cid hydrolysis conditions and can be used as proxies for quan-
itation of the parent peptide [6]. AAA is widely used for peptide
nd protein quantitation, this study only had four labs that per-
ormed the AAA test, which is not enough to draw a conclusion
bout using AAA for peptide quantitation. The survey result from oxytocin. a) oxytocin, b) caffeine, c) maleic acid, and d) 3-sulfolene.
this study reveals that the accuracy and precision are highly depen-
dent on the quantitation methods. The LC–MS method used by labs
3 and 7 gave low intra-lab variability, but this method used 13C
isotope-labeled amino acids as an internal standard, which is not
an established approach by pharmaceutical industry labs. The rou-
tine pre- or post-column derivatization methods used by Labs 2
and 9 have variability that is too high to be a top choice for peptide
quantitation.
4. Conclusions
In conclusion, the study described above demonstrates the
use and suitability of three distinct analytical methods for pep-
tide quantiﬁcation: HPLC, qNMR, and AAA. The merits of these
approaches and the signiﬁcance of the results achieved have been
evaluated statistically. In this study, the traditional HPLC assay
method using the same peptide bulk material as the standard had
the lowest inter-lab variability.
qNMR spectroscopy has been employed for value-assignment
of peptide reference standards [11,12]. qNMR for peptide quanti-
tation has also been evaluated through international comparison
exercises [13], and relative to amino acid analysis offers the advan-
tage of measuring peptides directly without the added complexity
and potential errors associated with acid hydrolysis. qNMR is
easy to perform under common laboratory conditions. Its accu-
racy and precision can be enhanced by selecting appropriate signals
from the peptide or selecting an internal standard that has non-
exchangeable and non-overlapping signals in D2O. The scope of
qNMR analysis can be also applied easily to peptide reference stan-
dards packaged by lyophilization.
The common peptide impurities are diastereomers, dele-
tion/insertion sequence, hydrolysis, oxidation, and N-, O- acety-
lation related [14]. NMR  is generally not suitable for quantiﬁcation
of these types of product-related impurities because they usu-
ally show similar 1D H NMR  spectra, thus making peak overlap
likely. HPLC, especially LC–MS, is an easier separation tool for
peptide product-related impurities. On the other hand, non-
product-related impurities such as solvents can often be detected
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nd quantitated by NMR. Statistical approaches would be required
n those situations. In this study, the values assigned by NMR  and
AA were not corrected for peptide related impurities, which in
heory could contribute a bias comparing with the results by HPLC.
he current study provides a promise for compendial adoption of
he qNMR methodology. However, the roadmap to approach the
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